Log in

NASDAQ:NYMX - Nymox Pharmaceutical Stock Price, Forecast & News

$2.86
+0.08 (+2.88 %)
(As of 02/28/2020 04:00 PM ET)
Today's Range
$2.20
Now: $2.86
$2.88
50-Day Range
$2.77
MA: $3.15
$3.88
52-Week Range
$1.32
Now: $2.86
$4.09
Volume294,633 shs
Average Volume286,230 shs
Market Capitalization$199.76 million
P/E RatioN/A
Dividend YieldN/A
Beta1.81
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease. Read More…

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NYMX
CUSIPN/A
Phone800-936-9669

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$300,000.00
Book Value$0.12 per share

Profitability

Net Income$-10,590,000.00
Net Margins-12,217.59%

Miscellaneous

EmployeesN/A
Market Cap$199.76 million
Next Earnings Date4/3/2020 (Estimated)
OptionableOptionable

Receive NYMX News and Ratings via Email

Sign-up to receive the latest news and ratings for NYMX and its competitors with MarketBeat's FREE daily newsletter.


Nymox Pharmaceutical (NASDAQ:NYMX) Frequently Asked Questions

What is Nymox Pharmaceutical's stock symbol?

Nymox Pharmaceutical trades on the NASDAQ under the ticker symbol "NYMX."

How were Nymox Pharmaceutical's earnings last quarter?

Nymox Pharmaceutical Corp (NASDAQ:NYMX) released its earnings results on Friday, November, 14th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter. The biopharmaceutical company earned $0.08 million during the quarter. Nymox Pharmaceutical had a negative net margin of 12,217.59% and a negative return on equity of 174.16%. View Nymox Pharmaceutical's Earnings History.

When is Nymox Pharmaceutical's next earnings date?

Nymox Pharmaceutical is scheduled to release their next quarterly earnings announcement on Friday, April 3rd 2020. View Earnings Estimates for Nymox Pharmaceutical.

Has Nymox Pharmaceutical been receiving favorable news coverage?

Press coverage about NYMX stock has trended very negative recently, according to InfoTrie. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Nymox Pharmaceutical earned a daily sentiment score of -4.0 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the stock's share price in the immediate future. View News Stories for Nymox Pharmaceutical.

Are investors shorting Nymox Pharmaceutical?

Nymox Pharmaceutical saw a increase in short interest in February. As of February 14th, there was short interest totalling 2,400,000 shares, an increase of 31.1% from the January 30th total of 1,830,000 shares. Based on an average daily trading volume, of 180,900 shares, the days-to-cover ratio is presently 13.3 days. Approximately 6.1% of the shares of the company are sold short. View Nymox Pharmaceutical's Current Options Chain.

Who are some of Nymox Pharmaceutical's key competitors?

What other stocks do shareholders of Nymox Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nymox Pharmaceutical investors own include Quantum (QTM), Rocket Pharmaceuticals (RCKT), NovaBay Pharmaceuticals (NBY), Biocept (BIOC), Synergy Pharmaceuticals (SGYP), TherapeuticsMD (TXMD), Catalyst Pharmaceuticals (CPRX), Rigel Pharmaceuticals (RIGL), MEI Pharma (MEIP) and Amarin (AMRN).

Who are Nymox Pharmaceutical's key executives?

Nymox Pharmaceutical's management team includes the folowing people:
  • Dr. Paul Averback, Founder, Chairman, CEO & Pres (Age 68)
  • Mr. Erik Danielsen, Chief Financial Officer (Age 56)
  • Mr. Randall J. Lanham, Gen. Counsel, Sec. & Director (Age 55)

Who are Nymox Pharmaceutical's major shareholders?

Nymox Pharmaceutical's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Bank of America Corp DE (0.16%), Wedbush Securities Inc. (0.06%), Goldman Sachs Group Inc. (0.06%), Patriot Financial Group Insurance Agency LLC (0.05%), Renaissance Technologies LLC (0.05%) and Credit Suisse AG (0.05%). Company insiders that own Nymox Pharmaceutical stock include Erik Danielsen, James George Robinson, Paul Averback and Randall J Lanham. View Institutional Ownership Trends for Nymox Pharmaceutical.

Which institutional investors are selling Nymox Pharmaceutical stock?

NYMX stock was sold by a variety of institutional investors in the last quarter, including Wedbush Securities Inc., Bank of America Corp DE and Willow Creek Wealth Management Inc.. View Insider Buying and Selling for Nymox Pharmaceutical.

Which institutional investors are buying Nymox Pharmaceutical stock?

NYMX stock was acquired by a variety of institutional investors in the last quarter, including Patriot Financial Group Insurance Agency LLC, Credit Suisse AG, Virtu Financial LLC, Renaissance Technologies LLC, Tower Research Capital LLC TRC , Goldman Sachs Group Inc. and Sunbelt Securities Inc.. Company insiders that have bought Nymox Pharmaceutical stock in the last two years include Erik Danielsen, James George Robinson and Randall J Lanham. View Insider Buying and Selling for Nymox Pharmaceutical.

How do I buy shares of Nymox Pharmaceutical?

Shares of NYMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Nymox Pharmaceutical's stock price today?

One share of NYMX stock can currently be purchased for approximately $2.86.

How big of a company is Nymox Pharmaceutical?

Nymox Pharmaceutical has a market capitalization of $199.76 million and generates $300,000.00 in revenue each year. View Additional Information About Nymox Pharmaceutical.

What is Nymox Pharmaceutical's official website?

The official website for Nymox Pharmaceutical is http://www.nymox.com/.

How can I contact Nymox Pharmaceutical?

Nymox Pharmaceutical's mailing address is 9900 CAVENDISH BLVD. SUITE 306, ST. LAURENT A8, H4M 2V2. The biopharmaceutical company can be reached via phone at 800-936-9669 or via email at [email protected]


MarketBeat Community Rating for Nymox Pharmaceutical (NASDAQ NYMX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  144 (Thanks for Voting!)
Underperform Votes:  149 (Thanks for Voting!)
Total Votes:  293
MarketBeat's community ratings are surveys of what our community members think about Nymox Pharmaceutical and other stocks. Vote "Outperform" if you believe NYMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NYMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel